These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 23625705)
1. Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors. Pryce G; Cabranes A; Fernández-Ruiz J; Bisogno T; Di Marzo V; Long JZ; Cravatt BF; Giovannoni G; Baker D Mult Scler; 2013 Dec; 19(14):1896-904. PubMed ID: 23625705 [TBL] [Abstract][Full Text] [Related]
2. Effects of fatty acid amide hydrolase (FAAH) inhibitors on working memory in rats. Panlilio LV; Thorndike EB; Nikas SP; Alapafuja SO; Bandiera T; Cravatt BF; Makriyannis A; Piomelli D; Goldberg SR; Justinova Z Psychopharmacology (Berl); 2016 May; 233(10):1879-88. PubMed ID: 26558620 [TBL] [Abstract][Full Text] [Related]
3. Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice. Walentiny DM; Vann RE; Wiley JL Neuropharmacology; 2015 Jun; 93():237-42. PubMed ID: 25698527 [TBL] [Abstract][Full Text] [Related]
5. Guineensine is a novel inhibitor of endocannabinoid uptake showing cannabimimetic behavioral effects in BALB/c mice. Nicolussi S; Viveros-Paredes JM; Gachet MS; Rau M; Flores-Soto ME; Blunder M; Gertsch J Pharmacol Res; 2014 Feb; 80():52-65. PubMed ID: 24412246 [TBL] [Abstract][Full Text] [Related]
6. The effects of fatty acid amide hydrolase and monoacylglycerol lipase inhibitor treatments on lipopolysaccharide-induced airway inflammation in mice. Abohalaka R; Bozkurt TE; Nemutlu E; Onder SC; Sahin-Erdemli I Pulm Pharmacol Ther; 2020 Jun; 62():101920. PubMed ID: 32416152 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate. Vandevoorde S; Fowler CJ Br J Pharmacol; 2005 Aug; 145(7):885-93. PubMed ID: 15895107 [TBL] [Abstract][Full Text] [Related]
8. Endocannabinoid contribution to Δ9-tetrahydrocannabinol discrimination in rodents. Wiley JL; Walentiny DM; Wright MJ; Beardsley PM; Burston JJ; Poklis JL; Lichtman AH; Vann RE Eur J Pharmacol; 2014 Aug; 737():97-105. PubMed ID: 24858366 [TBL] [Abstract][Full Text] [Related]
9. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Moreira FA; Kaiser N; Monory K; Lutz B Neuropharmacology; 2008 Jan; 54(1):141-50. PubMed ID: 17709120 [TBL] [Abstract][Full Text] [Related]
10. Full Fatty Acid Amide Hydrolase Inhibition Combined with Partial Monoacylglycerol Lipase Inhibition: Augmented and Sustained Antinociceptive Effects with Reduced Cannabimimetic Side Effects in Mice. Ghosh S; Kinsey SG; Liu QS; Hruba L; McMahon LR; Grim TW; Merritt CR; Wise LE; Abdullah RA; Selley DE; Sim-Selley LJ; Cravatt BF; Lichtman AH J Pharmacol Exp Ther; 2015 Aug; 354(2):111-20. PubMed ID: 25998048 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice. Nozaki C; Markert A; Zimmer A Eur Neuropsychopharmacol; 2015 Aug; 25(8):1388-96. PubMed ID: 25910421 [TBL] [Abstract][Full Text] [Related]
12. The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice. Booker L; Kinsey SG; Abdullah RA; Blankman JL; Long JZ; Ezzili C; Boger DL; Cravatt BF; Lichtman AH Br J Pharmacol; 2012 Apr; 165(8):2485-96. PubMed ID: 21506952 [TBL] [Abstract][Full Text] [Related]
13. Stimulation of diuresis and natriuresis by renomedullary infusion of a dual inhibitor of fatty acid amide hydrolase and monoacylglycerol lipase. Ahmad A; Daneva Z; Li G; Dempsey SK; Li N; Poklis JL; Lichtman A; Li PL; Ritter JK Am J Physiol Renal Physiol; 2017 Nov; 313(5):F1068-F1076. PubMed ID: 28768662 [TBL] [Abstract][Full Text] [Related]
14. Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease. Celorrio M; Fernández-Suárez D; Rojo-Bustamante E; Echeverry-Alzate V; Ramírez MJ; Hillard CJ; López-Moreno JA; Maldonado R; Oyarzábal J; Franco R; Aymerich MS Brain Behav Immun; 2016 Oct; 57():94-105. PubMed ID: 27318096 [TBL] [Abstract][Full Text] [Related]
16. Ex vivo imaging of fatty acid amide hydrolase activity and its inhibition in the mouse brain. Glaser ST; Gatley SJ; Gifford AN J Pharmacol Exp Ther; 2006 Mar; 316(3):1088-97. PubMed ID: 16278311 [TBL] [Abstract][Full Text] [Related]
17. Fatty acid amide hydrolase but not monoacyl glycerol lipase controls cell death induced by the endocannabinoid 2-arachidonoyl glycerol in hepatic cell populations. Siegmund SV; Wojtalla A; Schlosser M; Zimmer A; Singer MV Biochem Biophys Res Commun; 2013 Jul; 437(1):48-54. PubMed ID: 23806692 [TBL] [Abstract][Full Text] [Related]
18. Simultaneous inhibition of fatty acid amide hydrolase and monoacylglycerol lipase shares discriminative stimulus effects with Δ9-tetrahydrocannabinol in mice. Hruba L; Seillier A; Zaki A; Cravatt BF; Lichtman AH; Giuffrida A; McMahon LR J Pharmacol Exp Ther; 2015 May; 353(2):261-8. PubMed ID: 25711338 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Chang L; Luo L; Palmer JA; Sutton S; Wilson SJ; Barbier AJ; Breitenbucher JG; Chaplan SR; Webb M Br J Pharmacol; 2006 May; 148(1):102-13. PubMed ID: 16501580 [TBL] [Abstract][Full Text] [Related]